UAE Signs $2.5 Billion Deal to Supply Missile Boats to Kuwait

Emirati defense company EDGE Group PJSC signed a $2.45 billion deal to supply Kuwait with a fleet of missile boats, highlighting the United Arab Emirates' advances in homegrown military capabilities.
The contract with Kuwait's Defense Ministry is the Abu Dhabi-owned conglomerate's largest since launching in late 2019, a spokesperson for the company said on Wednesday. As the deal's prime contractor, EDGE will deliver 62-meter-long Falaj 3 vessels, including munitions. The company awarded Abu Dhabi Ship Building, its naval arm, a seven billion dirham ($1.9 billion) contract to build, procure, and provide logistic support.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

Nearly 1,000 ships see GPS jams near Iran coast, group says

Nearly 1,000 ships have experienced 'persistent and sometimes severe' GPS signal jams every day the past week near Iran as the country continues to face bombardment from Israel's military, a French naval monitoring firm warned Friday. The Maritime Information, Cooperation and Awareness (MICA) Center wrote in a post on the social platform X that the situation 'makes it harder to navigate safely at night, in poor visibility and/or when traffic density is heavy.' '[It] also can lead to accidental situations,' the group wrote. The MICA Center said it's possible the GPS issue may have contributed to the recent collision of two giant tankers, ADALYNN and Front Eagle, in the Gulf of Oman near the United Arab Emirates, but the organization cautioned that the crash remains under investigation. Israel and Iran have been exchanging strikes for the past week, after Israel launched a surprise attack against Iran's nuclear facilities and military sites. The MICA center noted that maritime trade was not being targeted in an analysis of the military conflict's impact on Wednesday. 'In spite of the media narrative of a potential blockade … there is no information pointing towards a blockade,' the group wrote. It urged ships to avoid Iranian territorial waters and be aware of potential GPS jamming. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Yahoo

9 hours ago

• Yahoo

Sanofi (ENXTPA:SAN) Gains FDA Approval For Dupixent To Address Rare Skin Disease

Sanofi experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing of a memorandum with the Department of Health - Abu Dhabi, signal positive developments for its collaborative efforts with Regeneron and internal growth strategies. Although these announcements are significant, they were not sufficient to counteract the broader move, which might have been influenced by other factors specific to Sanofi, such as its recent €1.5 billion notes offering aimed at supporting corporate purposes. Buy, Hold or Sell Sanofi? View our complete analysis and fair value estimate and you decide. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The recent developments for Sanofi, including FDA approval of Dupixent for a rare skin condition and the memorandum with the Department of Health - Abu Dhabi, highlight efforts to enhance revenue growth through expanded market reach and innovation. Despite these positive updates, Sanofi shares experienced a 4% decline over the past week, influenced by factors such as the recent €1.5 billion notes offering. Over a longer-term period, Sanofi achieved a total shareholder return of 11.29% over five years. Comparatively, over the past year, Sanofi's performance matched the French Pharmaceuticals industry, which reported a similar decline of 5.9%. In contrast, the broader French Market fared slightly better, returning 2.2%. The recent news related to Dupixent and international partnerships could potentially boost Sanofi's revenue and earnings forecasts, providing a catalyst for future growth given the innovative pipeline and market penetration opportunities. Considering the current share price of €95.9 and the analyst consensus price target of €117.7, there is potential for an 18.5% increase, according to market projections. These developments need to be weighed against existing market conditions and company fundamentals, as analysts remain divided on future earnings prospects and valuations. Click here to discover the nuances of Sanofi with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:SAN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Associated Press

10 hours ago

• Associated Press

Solytics Partners Appoints Financial Crime Compliance Expert Sunil Kavishwar to Advisory Board to Strengthen AML Efforts in the GCC

DUBAI, AE / ACCESS Newswire / June 21, 2025 / Solytics Partners, a global leader in regulatory technology and AML/Financial Crime Compliance (FCC) solutions, is pleased to announce the appointment of Sunil Kavishwar to its Advisory Board. Sunil will support the firm's mission to drive compliance transformation and regulatory innovation across the Gulf Cooperation Council (GCC) region. Bringing over 20 years of experience in AML, sanctions compliance, and regulatory supervision, Sunil has held senior roles at the Central Bank of the UAE (CBUAE), First Abu Dhabi Bank, EY, and Accenture. He has played a leading role in shaping regional financial crime frameworks and public-private initiatives. Sunil's unparalleled experience in shaping the financial crime compliance landscape in the UAE makes him an invaluable addition to our team,' said Vikas Tyagi, CEO at Solytics Partners. 'His regulatory insights, public-private leadership, and strategic execution capabilities will be pivotal as we expand our footprint across the Middle East. ' Sunil was instrumental in establishing the UAE's first financial crime supervision framework at the CBUAE, covering institutional risk analysis, CRS/FATCA tax transparency, and virtual asset regulation. He also led the development of FATF-aligned frameworks and helped shape national policies on cross-border data sharing and sectoral risk assessments-strengthening the UAE's financial system integrity. Driving RegTech Growth in the GCC Sunil's appointment is a key milestone in Solytics Partners' strategy to accelerate the adoption of intelligent AML and sanctions solutions in the region. He will help build stronger ties with regulatory authorities and financial institutions, promoting alignment with global standards and enabling technology-driven compliance transformation. 'Solytics Partners has built a comprehensive and forward-looking FCC ecosystem,' said Sunil Kavishwar. 'I'm excited to support its mission and help institutions in the region to enhance compliance effectiveness while meeting regulatory expectations through intelligent solutions.' About Solytics Partners Solytics Partners is a global provider of RegTech solutions that streamline compliance, risk management, and regulatory reporting for financial institutions. Leveraging AI, machine learning, and advanced analytics, Solytics enables its clients to combat financial crime, improve risk oversight, and operate more efficiently. With a strong focus on the Middle East and emerging markets, Solytics Partners delivers customized, scalable solutions for AML compliance, transaction monitoring, sanctions screening, and risk assessments-helping clients stay ahead of evolving regulatory landscapes. Contact InformationDeepak Mehta Investor Relations +1-6468223440 SOURCE: Solytics Partners press release